Dexrazoxane (ICRF-187). (Q40828883)

24 September 2017

1 reference

title

Dexrazoxane (ICRF-187). (English)

1 reference

24 September 2017

1

Weiss G

1 reference

24 September 2017

Loyevsky M

2

1 reference

PubMed ID

9888268

24 September 2017

Gordeuk VR

series ordinal

3

1 reference

24 September 2017

1 January 1999

1 reference

24 September 2017

1 reference

24 September 2017

32

1 reference

24 September 2017

1

1 reference

24 September 2017

155-158

1 reference

Strategies for prevention of anthracycline cardiotoxicity

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187)

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Iron sequestration by macrophages decreases the potential for extracellular hydroxyl radical formation

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Mode of Action of the Cytostatic Agent ‘ICRF 159’

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

In vitro effects of three iron chelators on mitogen-activated lymphocytes: identification of differences in their mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Linkage of cell-mediated immunity to iron metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2898%2900100-1

7 January 2021

10.1016/S0306-3623(98)00100-1

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9888268